Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio

Radnostix, Inc. has announced the successful acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform and ELLEXA® Explorer software, in a deal valued at an undisclosed amount. The transaction was finalized on July 2, 2026, and positions Radnostix to enhance its offerings in the medical devices sector, specifically within the radiopharmaceuticals market.

The LARA® System and ELLEXA® Explorer software are designed to improve dosimetry and reduce the incidence of extravasations during the intravenous administration of radiopharmaceuticals. The technology has recently been upgraded to include a Real-Time Visualization feature, allowing clinicians to address extravasations as they occur, thereby enhancing patient safety during theranostic procedures. This capability is particularly significant given the increasing demand for effective and safe nuclear medicine solutions.

Radnostix, a company established in 1995 and headquartered in Idaho Falls, Idaho, specializes in radioisotope production and nuclear medicine solutions. The acquisition aligns with Radnostix's strategic objective to broaden its product portfolio and establish itself as a comprehensive solutions provider in the theranostics market. By integrating the acquired intellectual property into its existing offerings, Radnostix aims to develop innovative tools for drug uptake monitoring and dosimetry systems, which could lower entry barriers for clinics and improve overall safety and efficiency in radiopharmaceutical administration.

The acquisition also reflects broader trends within the medical devices sector, particularly the growing focus on patient safety and the need for advanced monitoring solutions in nuclear medicine. As the market for radiopharmaceuticals continues to expand, driven by advancements in theranostics and personalized medicine, companies like Radnostix are well-positioned to capitalize on these developments by enhancing their technological capabilities and product offerings.

In conclusion, Radnostix's acquisition of Lucerno Dynamics' assets marks a significant step in its growth strategy within the medical devices sector. By leveraging the LARA® System and ELLEXA® Explorer software, Radnostix is set to enhance its competitive position in the radiopharmaceutical market. As the demand for innovative and safe nuclear medicine solutions increases, this acquisition may lead to new product developments that further improve patient outcomes and safety in the administration of radiopharmaceuticals.